Monthly Archives: February 2023

Hot Business News Today

Zinzino January Sales Up 18% To $11 Million

by  •  • 0 Comments

According to a Zinzino Press release:
The revenue in January for Zinzino’s sales markets increased by 18% and amounted to SEK 120.0 (102.1) million.
Faun Pharma’s external sales increased by 32% and amounted to SEK 9.1 (6.9) million. Overall, the Group increased revenues by 18% to SEK 129.1(109.0) million compared with the previous year.
Revenues were distributed as follows (10 Million Swedish Krona = approx. $1 Million USD)

Regions, mSEK
23/Jan
22/Jan
Change

The Nordics
23,1
26
-11 %

Central Europe
28,5
18,4
55 %

East Europe
32,8
28,6
15 %

South & West Europe
15,9
12,1
31 %

The Baltics
7,4
6,5
14 %

North America
6,3
4,4
43 %

Asia-Pacific
4,6
5,7
-19 %

Africa
1,4
0,4
250 %

Zinzino
120
102,1
18 %

Faun Pharma
9,1
6,9
32 %

Zinzino Group
129,1
109
18 %

The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden.
Central Europe: Austria, Germany, Switzerland.
East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania.
South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland.
The Baltics: Estonia, Latvia, Lithuania.
North America: Canada, USA.
Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand.
Africa: South Africa.

About Zinzino
Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the research unit BioActive Foods AS and production unit Faun Pharma AS.
Zinzino is based in Gothenburg, with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong and Malaysia. Zinzino is a public company and its shares are listed on Nasdaq First North Premier Growth Market. For more informaton please visit www.zinzino.com
The post Zinzino January Sales Up 18% To $11 Million appeared first on

Read more...

Hot Business News Today

StemTech Launches In Colombia

by  •  • 0 Comments

President and Chief Operating Officer, John W. Meyer, says:
“Stemtech has started working to launch Stemtech Colombia with our country offices intended to be located in Bogota. During our Leadership Event held last December 2022 in Cancun, Mexico, we were requested by our Field leaders to undertake opening a Colombia office.
Given the existing relationships between our Latin American Independent Business Partners (IBPs) and residents in that country. This also fits into our company concept of ‘Just One More’ by adding a new market”.
Stemtech CEO, Charles S. Arnold, says:
“Colombia is a very exciting market for Stemtech as it is a great country in which to introduce the health and wellness benefits of our anti-aging, all-natural, plant-based stemceutical™ products.
In addition, technology advances we have made with our AdvanceOffice mobile app, will help to provide leading-edge communication and easier recruiting tools for our IBPs to share the Stemtech opportunity for building an entrepreneurial business for Colombian citizens with the opportunity to earn additional income”.
Stemtech`s Vice President of Global Sales, Alejandro Carrillo states:
“the VISION 2023 strategic business plan initiative includes expansion of our Latin American markets. This is the first step toward achieving this objective this year. Colombia is an opportunity as one

Read more...

Hot Business News Today

LifeVantage Sales Up 2.8% To $53.7 Million

by  •  • 0 Comments

LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its second fiscal quarter ended December 31, 2022.
Second Quarter Fiscal 2023 Summary*:

Revenue of $53.7 million, an increase of 2.8% from the prior year period. Excluding the negative impact of foreign currency fluctuations, second quarter revenue was up approximately 7.4%;
Revenue in the Americas increased 14.4% including a 15.4% increase in the United States. Revenue in Asia/Pacific & Europe decreased 20.2% and was down approximately 7.0% excluding the negative impact of foreign currency fluctuations;
Total active accounts declined 8.6% from the prior year period to 149,000, reflecting a decline of 7.1% in the Americas and a 12.0% decline in Asia/Pacific & Europe;
Net loss per diluted share were $0.08, versus net income of $0.01 per diluted share a year ago;
Adjusted loss per diluted share were $0.07, versus adjusted earnings per diluted share of $0.05 a year ago;
Adjusted EBITDA of $0.8 million, compared to $1.9 million a year ago; and
Strong balance sheet with $17.4 million of cash and no debt.

* All comparisons are on a year over year basis and compare the second quarter of fiscal 2023 to the second quarter of fiscal 2022, unless otherwise noted.

“We reached a positive inflection point in the second quarter, delivering year-over-year revenue growth of

Read more...